AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30949742 — intervention group
Group type: EXPERIMENTAL
Intervention: B.T. Enema (sodium dihydrogen phosphate + disodium hydrogen phosphate) 135 ml
Number of subjects: 95
Study 30949742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enema)
Number of subjects: 95
Study 30949742 — intervention group
Group type: COMPARATOR
Intervention: Both groups (enema and control)
Number of subjects: 95
Study 29558513 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 46
Study 29558513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 46
Study 29558513 — intervention group
Group type: COMPARATOR
Intervention: tDCS (anodal and cathodal)
Number of subjects: 46
Study 26470647 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS 2G drug-eluting absorbable metal scaffold
Number of subjects: 123
Study 26227657 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural drainage
Number of subjects: 141
Study 26227657 — intervention group
Group type: COMPARATOR
Intervention: Negative drainage
Number of subjects: 141
Study 23835329 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 23835329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 30
Study 23835329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22152750 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring with nurse-led support
Number of subjects: 381
Study 19307994 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oregovomab infusion on the same day as chemotherapy (SIM)
Number of subjects: 40
Study 19307994 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oregovomab infusion 1 week after chemotherapy (OWD)
Number of subjects: 40
Study 19307994 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oregovomab infusion (both SIM and OWD)
Number of subjects: 40
Study 19307994 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-line chemotherapy with carboplatin-paclitaxel
Number of subjects: 40
Study 19307994 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-line chemotherapy with carboplatin-paclitaxel combined with oregovomab
Number of subjects: 40
Study 16391383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of nitroprusside
Number of subjects: 40
Study 16391383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of adenosine
Number of subjects: 40
Study 16391383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of verapamil
Number of subjects: 40
Study 16391383 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary injection of nitroglycerin (control group)
Number of subjects: 40
Study 15172648 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical Amiodarone
Number of subjects: 214
Study 15172648 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiology-guided interventions
Number of subjects: 214
Study 15172648 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD recipients
Number of subjects: 214
Study 10647318 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Restoration (FR) program
Number of subjects: 816
Study 10647318 — intervention group
Group type: COMPARATOR
Intervention: Control programs (shorter outpatient programs or no treatment)
Number of subjects: 816
Study 9302302 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous drainage with albendazole (10 mg/kg/day for 8 weeks)
Number of subjects: 50
Study 9302302 — intervention group
Group type: COMPARATOR
Intervention: Surgery (cystectomy)
Number of subjects: 50
Study 9302302 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous drainage
Number of subjects: 50
Study 9302302 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 50
Study 8331011 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO) at a dose of 200 units/kg/day, five times a week with iron supplements (Fe SO4, 325 mg. p.o., t.i.d.)
Number of subjects: 26
Study 8331011 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving radiotherapy without r‐HuEPO
Number of subjects: 26
Study 3304952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (3.2 g daily in 2 doses)
Number of subjects: 10
Study 3304952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3304952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate with concomitant cholestyramine (16 g daily)
Number of subjects: 10
Study 3304952 — intervention group
Group type: COMPARATOR
Intervention: Placebo with concomitant cholestyramine (16 g daily)
Number of subjects: 10
Study 30249587 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based teaching using the Mentice VIST-Lab CA simulator (n=59, SIM group)
Number of subjects: 118
Study 30249587 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based teaching (n=59, SIM group)
Number of subjects: 118
Study 30249587 — intervention group
Group type: COMPARATOR
Intervention: Control teaching group (n=59, CONT group)
Number of subjects: 118
Study 26433452 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast served in the classroom
Number of subjects: 3944
Study 26433452 — intervention group
Group type: COMPARATOR
Intervention: Breakfast served in the cafeteria before school
Number of subjects: 3944
Study 26433452 — intervention group
Group type: COMPARATOR
Intervention: Second chance breakfast (in the cafeteria before school and again at first recess)
Number of subjects: 3944
Study 24057894 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training (3 sets of 12-15 repetitions, intensity 60-70% of one repetition maximum, four 50-minute sessions per week)
Number of subjects: 56
Study 24057894 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 56
Study 24057894 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TG and CG)
Number of subjects: 56
Study 24057894 — intervention group
Group type: COMPARATOR
Intervention: Barthel Index (stairs)
Number of subjects: 56
Study 22889084 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switching implants (58 implants restored with medialised abutments)
Number of subjects: 54
Study 22889084 — intervention group
Group type: COMPARATOR
Intervention: Standard platform implants (56 implants restored with standard matching-diameter abutments)
Number of subjects: 54
Study 20019316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 16
Study 20019316 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 18701826 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum PL03, Lactobacillus rhamnosus KL53A, Lactobacillus plantarum PL02)
Number of subjects: 78
Study 18701826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 22122599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spots (DBS) assay for guanfacine
Number of subjects: 12
Study 22122599 — intervention group
Group type: COMPARATOR
Intervention: Plasma bioanalysis
Number of subjects: 12
Study 15752888 — intervention group
Group type: EXPERIMENTAL
Intervention: RT/CCT (70 to 72.5 Gy accelerated hyperfractionated RT at 1.25 Gy b.i.d. with 2 cycles of CDDP (12‐20 mg/m(2)/d x 5 days) and continuous infusion 5‐FU (600 mg/m(2)/d x 5 days) during Week 1 and Week 6)
Number of subjects: 159
Study 15752888 — intervention group
Group type: COMPARATOR
Intervention: RT alone (control group)
Number of subjects: 159
Study 11890430 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic technique, lumbar spine flexion‐distraction, combined with manual Trigger Point Therapy
Number of subjects: 39
Study 11890430 — intervention group
Group type: COMPARATOR
Intervention: Sham chiropractic procedure performed with an instrument combined with effleurage (light massage)
Number of subjects: 39
Study 9711053 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms levothyroxine and 150 micrograms iodide (group A, n = 25)
Number of subjects: 48
Study 9711053 — intervention group
Group type: COMPARATOR
Intervention: 150 micrograms levothyroxine (group B, n = 23)
Number of subjects: 48
Study 7653696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day, flexible dosing)
Number of subjects: 12
Study 7653696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2672480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with fluorouracil (5‐FU) (400 mg/m2 i.v., days 1‐5) and lomustine (CCNU) (100 mg/m2 per os on day 5) every 6 weeks for 9 cycles
Number of subjects: 263
Study 2672480 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (surgery alone)
Number of subjects: 263
Study 2672480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with fluorouracil (5‐FU) and lomustine (CCNU)
Number of subjects: 263
Study 55646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural B.C.G.
Number of subjects: 60
Study 55646 — intervention group
Group type: COMPARATOR
Intervention: Control (no B.C.G. treatment)
Number of subjects: 60
Study 11722851 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping intervention for patients with rheumatic diseases
Number of subjects: 0
Study 31288289 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT 1:2 (30:60s)
Number of subjects: 47
Study 31288289 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT 1:4 (30:120s)
Number of subjects: 47
Study 31288289 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT 1:8 (30:240s)
Number of subjects: 47
Study 31288289 — intervention group
Group type: COMPARATOR
Intervention: Control group (Taekwondo training program)
Number of subjects: 47
Study 28425672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 2
Study 28425672 — intervention group
Group type: COMPARATOR
Intervention: Gaussian model
Number of subjects: 2
Study 26957290 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 325 mg/tramadol 37.5 mg
Number of subjects: 44
Study 26957290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25379859 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 1236
Study 25379859 — intervention group
Group type: COMPARATOR
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 1236
Study 22591502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 5-aminolevulinic acid (IL-ALA) plus intense pulsed light (IPL)
Number of subjects: 30
Study 22591502 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) alone
Number of subjects: 30
Study 20429333 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive axillary dissection
Number of subjects: 56
Study 20429333 — intervention group
Group type: COMPARATOR
Intervention: Classical axillary dissection
Number of subjects: 56
Study 18330060 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine ORS
Number of subjects: 147
Study 18330060 — intervention group
Group type: COMPARATOR
Intervention: WHO-ORS
Number of subjects: 147
Study 15893170 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg folic acid
Number of subjects: 14
Study 15893170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12905551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesorectal excision
Number of subjects: 311
Study 12905551 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 311
Study 10608624 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐T (Hib conjugate vaccine combined with DTP)
Number of subjects: 0
Study 8768157 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum splint
Number of subjects: 0
Study 8768157 — intervention group
Group type: COMPARATOR
Intervention: Rigid backboard
Number of subjects: 0
Study 1750637 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal blockade with bupivacaine 20 ml 0.5%
Number of subjects: 40
Study 6785799 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (200-600 mg for 1 year)
Number of subjects: 22
Study 6785799 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 22
Study 30677019 — intervention group
Group type: EXPERIMENTAL
Intervention: Free delivery of ORS prior to illness (free and convenient)
Number of subjects: 118
Study 30677019 — intervention group
Group type: EXPERIMENTAL
Intervention: Home sales of ORS prior to illness (convenient only)
Number of subjects: 118
Study 30677019 — intervention group
Group type: EXPERIMENTAL
Intervention: Free ORS upon retrieval using voucher (free only)
Number of subjects: 118
Study 30677019 — intervention group
Group type: COMPARATOR
Intervention: Status quo CHW distribution (control)
Number of subjects: 118
Study 30448803 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution
Number of subjects: 50
Study 30448803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 15%
Number of subjects: 50
Study 27264227 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive customized intervention
Number of subjects: 2000
Study 27264227 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 2000
Study 24814408 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (G2)
Number of subjects: 36
Study 24814408 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading (G1)
Number of subjects: 36
Study 24814408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 36
Study 22358586 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctal plugs
Number of subjects: 18
Study 22358586 — intervention group
Group type: COMPARATOR
Intervention: Non-plug group
Number of subjects: 18
Study 20850365 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d) + calcium (500 mg/d) (n=23)
Number of subjects: 125
Study 20850365 — intervention group
Group type: COMPARATOR
Intervention: Placebo + calcium (500 mg/d) (n=23)
Number of subjects: 125
Study 20850365 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated (n=12)
Number of subjects: 125
Study 20850365 — intervention group
Group type: EXPERIMENTAL
Intervention: Any raloxifene treatment
Number of subjects: 125
Study 17135218 — intervention group
Group type: EXPERIMENTAL
Intervention: TV‐IVC ablation +/‐ DC cardioversion (group B, n = 27)
Number of subjects: 57
Study 17135218 — intervention group
Group type: COMPARATOR
Intervention: External cardioversion (group A, n = 30)
Number of subjects: 57
Study 17135218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 16361623 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection (APR)
Number of subjects: 0
Study 16361623 — intervention group
Group type: COMPARATOR
Intervention: Anterior resection (AR)
Number of subjects: 0
Study 12195168 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak clipping hearing aid circuit
Number of subjects: 360
Study 12195168 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression limiting hearing aid circuit
Number of subjects: 360
Study 12195168 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide dynamic range compression hearing aid circuit
Number of subjects: 360
Study 12195168 — intervention group
Group type: COMPARATOR
Intervention: Unaided condition
Number of subjects: 360
Study 9607544 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric substitute (S-shaped pouch)
Number of subjects: 36
Study 9607544 — intervention group
Group type: COMPARATOR
Intervention: Total gastrectomy without gastric substitute
Number of subjects: 36
Study 7618064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fishermen
Number of subjects: 250
Study 7618064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fishermen from the east coast
Number of subjects: 250
Study 7618064 — intervention group
Group type: COMPARATOR
Intervention: Referents
Number of subjects: 250
Study 2693406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 40 mg t.i.d.
Number of subjects: 89
Study 2693406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 703670 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-Cyanidanol-3 at a dosage of 6 tablets per day (3000 mg per day)
Number of subjects: 0
Study 703670 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-Cyanidanol-3 at a dosage of 3 X 1 tablet per day
Number of subjects: 0
Study 703670 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-Cyanidanol-3 at a dosage of 2 X 3 or 3 X 2 tablets per day
Number of subjects: 0
Study 703670 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-Cyanidanol-3 at all dose levels
Number of subjects: 0
Study 31775729 — intervention group
Group type: EXPERIMENTAL
Intervention: DQTM tablet (Dan Qi Tong Mai tablet) at single doses of up to 5760 mg
Number of subjects: 84
Study 31775729 — intervention group
Group type: EXPERIMENTAL
Intervention: DQTM tablet (Dan Qi Tong Mai tablet) at twice-daily doses of up to 2160 mg for 14 consecutive days
Number of subjects: 84
Study 31775729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 84
Study 31775729 — intervention group
Group type: EXPERIMENTAL
Intervention: DQTM tablet
Number of subjects: 84
Study 27310527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (SDX) with Diosmin-Hesperidin (DH)
Number of subjects: 70
Study 27310527 — intervention group
Group type: COMPARATOR
Intervention: Control group (Diosmin-Hesperidin (DH) only)
Number of subjects: 70
Study 26522871 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise (45-50 min/week three times a week for four months) plus pharmacotherapy
Number of subjects: 26
Study 26522871 — intervention group
Group type: COMPARATOR
Intervention: Only antidepressant medication
Number of subjects: 26
Study 23625076 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial to ulnar pattern of digit contact timing (DCT)
Number of subjects: 0
Study 23625076 — intervention group
Group type: EXPERIMENTAL
Intervention: Total contact time, frequency of first contacts by thumb and index fingers, number of simultaneous contacts
Number of subjects: 0
Study 20948512 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and pharmacologic treatment
Number of subjects: 82
Study 20439549 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 long-chain polyunsaturated fatty acid (omega3 LC-PUFA) supplementation
Number of subjects: 28
Study 20439549 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 long-chain polyunsaturated fatty acid (omega3 LC-PUFA) supplementation with greater than 50% EPA
Number of subjects: 28
Study 20439549 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure ethyl-EPA supplementation
Number of subjects: 28
Study 20439549 — intervention group
Group type: COMPARATOR
Intervention: Pure DHA supplementation
Number of subjects: 28
Study 20439549 — intervention group
Group type: COMPARATOR
Intervention: Supplements containing greater than 50% DHA
Number of subjects: 28
Study 17335293 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy followed by surgical resection
Number of subjects: 0
Study 17335293 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical therapy with chemoradiotherapy
Number of subjects: 0
Study 17335293 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 0
Study 15382984 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater projection
Number of subjects: 0
Study 15382984 — intervention group
Group type: EXPERIMENTAL
Intervention: Less stereotyping
Number of subjects: 0
Study 15382984 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction time results
Number of subjects: 0
Study 11300179 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall community violence trends from A&E data collection
Number of subjects: 121475
Study 11300179 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal trends in community violence
Number of subjects: 121475
Study 10331614 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAXA premutation carriers with POF having low copy of the (TA)n polymorphism
Number of subjects: 52
Study 10331614 — intervention group
Group type: COMPARATOR
Intervention: Familial POF
Number of subjects: 52
Study 10331614 — intervention group
Group type: COMPARATOR
Intervention: FRAXA premutation carriers without POF
Number of subjects: 52
Study 8589019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 966
Study 8589019 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 3 mg
Number of subjects: 966
Study 2186058 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-329 (10 mg)
Number of subjects: 8
Study 2186058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7194062 — intervention group
Group type: EXPERIMENTAL
Intervention: etofylline clofibrate 500 mg daily (2 x 1 capsule)
Number of subjects: 100
Study 7194062 — intervention group
Group type: EXPERIMENTAL
Intervention: etofylline clofibrate 750 mg daily (3 x 1 capsule)
Number of subjects: 100
Study 7194062 — intervention group
Group type: EXPERIMENTAL
Intervention: etofylline clofibrate (both dosages)
Number of subjects: 100
Study 30691405 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity program (MEFAP) with twelve 1.5 h-weekly sessions
Number of subjects: 190
Study 30691405 — intervention group
Group type: COMPARATOR
Intervention: Regular medical practice (Control)
Number of subjects: 190
Study 28323916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone infusion (0.2 mg/kg/min for 14 hours)
Number of subjects: 17
Study 28323916 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 17
Study 25902326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block (TAPB)
Number of subjects: 45
Study 25902326 — intervention group
Group type: COMPARATOR
Intervention: Caudal Block
Number of subjects: 45
Study 23870763 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐shirt made of 100% polyester with 4 channels
Number of subjects: 8
Study 23870763 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐shirt made of 100% polyester with 6 channels
Number of subjects: 8
Study 23870763 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐shirt made of 100% polyester with 8 channels
Number of subjects: 8
Study 23870763 — intervention group
Group type: COMPARATOR
Intervention: T‐shirt made of 100% cotton
Number of subjects: 8
Study 21551990 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ankle dorsiflexion (PAD) for one minute
Number of subjects: 20